prikaz prve stranice dokumenta Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Original scientific paper
Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia
Kidney & blood pressure research, 34 (2011), 1; 53-57. https://doi.org/10.1159/000322922
Bašić-Jukić, Nikolina; Gulin, Marijana; Slaviček, Jasna; Čorić Martinović, Valentina; Iskra, Bosiljka; Rački, Sanjin; Šain, Milenka; Ostojić, Rajko; Hrstić, Irena; Ljutić, Dragan; Vucelić, Boris; Kes, Petar

Cite this document

Bašić Jukić, N., Gulin, M., Slaviček, J., Čorić Martinović, V., Iskra, B., Rački, S. ... Kes, P. (2011). Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia. Kidney & blood pressure research, 34. (1), 53-57. doi: 10.1159/000322922

Bašić Jukić, Nikolina, et al. "Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia." Kidney & blood pressure research, vol. 34, no. 1, 2011, pp. 53-57. https://doi.org/10.1159/000322922

Bašić Jukić, Nikolina, Marijana Gulin, Jasna Slaviček, Valentina Čorić Martinović, Bosiljka Iskra, Sanjin Rački, Milenka Šain, et al. "Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia." Kidney & blood pressure research 34, no. 1 (2011): 53-57. https://doi.org/10.1159/000322922

Bašić Jukić, N., et al. (2011) 'Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia', Kidney & blood pressure research, 34(1), pp. 53-57. doi: 10.1159/000322922

Bašić Jukić N, Gulin M, Slaviček J, Čorić Martinović V, Iskra B, Rački S, and sur.. Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia. Kidney & blood pressure research [Internet]. 2011 [cited 2024 December 26];34(1):53-57. doi: 10.1159/000322922

N. Bašić Jukić, et al., "Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia", Kidney & blood pressure research, vol. 34, no. 1, pp. 53-57, 2011. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:707696. [Accessed: 26 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Pegylated interferon for treatment of chronic hepatitis C in hemodialysis patients in Croatia
AuthorNikolina Bašić-Jukić
AuthorMarijana Gulin
AuthorJasna Slaviček
AuthorValentina Čorić Martinović
AuthorBosiljka Iskra
AuthorSanjin Rački
AuthorMilenka Šain
AuthorRajko Ostojić
AuthorIrena Hrstić
AuthorDragan Ljutić
AuthorBoris Vucelić
AuthorPetar Kes
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Hepatitis C virus (HCV) infection is a frequent complication among long-term dialysis patients. The aim of the present study was to evaluate the efficacy and side effects of pegylated interferon-α(2a) (PEG-IFN-α(2a)) treatment in hemodialysis patients. We retrospectively reviewed charts of 16 HCV-RNA-positive hemodialysis patients. There were 11 male and 5 female patients treated with dialysis for 6-28 years. Twelve patients had HCV genotype 1b, 2 patients had 3a, and 1 patient had genotype 2a. Although only 10 out of 16 patients completed 48 weeks of treatment, early virological response and end-of-treatment virological response were achieved in 9 and 13 patients, respectively. Sustained virological response was recorded in 9 patients. The most common side effect was anemia. A flu-like syndrome was documented in 6, myalgia in 4, and arthralgia in 5 patients. Rectorrhagia, endocarditis and severe cough were recorded in 1 patient each. Nine patients received a renal transplant, and all 6 responders remained HCV-RNA-negative. PEG-IFN-α(2a) has limited efficacy in dialysis patients. A significant proportion of patients discontinued treatment because of side effects. Additional studies with long-term follow-up are needed to determine the optimal treatment of HCV infection in the dialysis population.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleKidney & blood pressure research
Numberingvol. 34, no. 1, pp. 53-57
p-ISSN1420-4096
DOIhttps://doi.org/10.1159/000322922
URN:NBNurn:nbn:hr:184:707696
Publication2011
ProjectNumber: 062-0000000-3550
Title (croatian): Molekularni mehanizmi infekcije virusom hepatitisa C
Title (english): Molecular mechanisms of infection with hepatitis C virus
Leader: Blaženka Grahovac
Jurisdiction: Croatia
Funding stream: ZP
ProjectNumber: 108-0000000-3499
Title (croatian): Prevencija, rano prepoznavanje i liječenje kroničnog zatajenja bubrega
Title (english): Prevention, early detection and tretament of chronic renal failure
Leader: Petar Kes
Jurisdiction: Croatia
Funding stream: ZP
ProjectNumber: 108-1080134-0122
Title (croatian): Čimbenici rizika za razvoj ateroskleroze nakon transplantacije bubrega
Title (english): Risk factors for development of atherosclerosis after renal transplantation
Leader: Nikolina Bašić-Jukić
Jurisdiction: Croatia
Funding stream: ZP
Document URLhttp://bib.irb.hr/544630
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2022-04-20 09:48:37